Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
She joins Enveda from Gilead Sciences
Subscribe To Our Newsletter & Stay Updated